<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02610374</url>
  </required_header>
  <id_info>
    <org_study_id>15-1692</org_study_id>
    <nct_id>NCT02610374</nct_id>
  </id_info>
  <brief_title>Diet / Gut Microbiome Interaction and Influence on Inflammatory Disease in HIV Patients</brief_title>
  <official_title>Diet / Gut Microbiome Interaction and Influence on Inflammatory Disease in HIV Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the effect of short-term diet modification on the&#xD;
      microbiome composition, and inflammatory/metabolic disease markers in Antiretroviral therapy&#xD;
      (ART)-treated HIV-infected participants and Human immunodeficiency virus (HIV)-negative&#xD;
      controls in the United States.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized clinical trial. Fifty (50) Antiretroviral therapy (ART)-treated Human&#xD;
      immunodeficiency virus (HIV) positive participants, 24 HIV negative controls matched for age&#xD;
      and sex, and 24 HIV negative controls from a population at high risk for contracting HIV will&#xD;
      be recruited into 3 cohorts. All participants will undergo a 4 week diet modification and&#xD;
      will be randomly assigned to receive either an Agrarian diet or a Western-type diet. For the&#xD;
      first 2 weeks, food will be provided to the participant, followed by an additional 2 weeks&#xD;
      where participants will be provided a diet menu with recipes to prepare themselves. There&#xD;
      will be 4 study visits and participation will last for up to 2 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma IL-6 concentration (All Participants)</measure>
    <time_frame>4 weeks</time_frame>
    <description>- The change in plasma IL-6 from baseline to week 4 for all participants (Cohorts A, B &amp; C) assigned to the Agrarian diet group will be compared to participants assigned to the Western diet group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma IL-6 concentration (HIV-Infected Participants)</measure>
    <time_frame>4 weeks</time_frame>
    <description>- The change in plasma IL-6 from baseline to week 4 for HIV-infected participants (Cohort A) assigned to an Agrarian diet will be compared to HIV-uninfected participants (Cohort B &amp; C) assigned to an Agrarian diet.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HIV-positive individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HIV-negative high-risk individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HIV-negative low-risk individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Agrarian Diet</intervention_name>
    <description>A diet higher in carbohydrates and lower in fats and sugars</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Western-type Diet</intervention_name>
    <description>A diet higher in fats and lower in carbohydrates</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-infected cohort (Cohort A)&#xD;
&#xD;
               -  Documentation of HIV-1 infection defined as a positive antibody test or plasma&#xD;
                  HIV-1 RNA (ribosomal ribonucleic acid).&#xD;
&#xD;
               -  Treated with ART (minimum of three antiretroviral drugs in regimen) for at least&#xD;
                  12 months with no changes in antiretroviral drugs over the past 6 months&#xD;
&#xD;
               -  Plasma HIV-1 RNA ≤ 50 copies/mL in the preceding 6 months.&#xD;
&#xD;
          -  HIV-negative cohorts (Cohort B and C)&#xD;
&#xD;
               -  Documentation of a negative HIV-1 antibody test&#xD;
&#xD;
          -  All Cohorts&#xD;
&#xD;
               -  Age 18 to 65 years&#xD;
&#xD;
               -  Body mass index between 21-29 kg/m2 (non-obese)&#xD;
&#xD;
               -  Stable weight for at least 3 months (≤15% change in body weight)&#xD;
&#xD;
               -  Negative pregnancy test (if female)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of systemic (oral or parenteral) antibiotics within two months prior to study&#xD;
             entry&#xD;
&#xD;
          -  Active chronic infection such as hepatitis B or C or an active malignancy that&#xD;
             requires systemic chemotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Lozupone, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Lozupone, PhD</last_name>
    <phone>303-724-7942</phone>
    <email>catherine.lozupone@ucdenver.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Lozupone, PhD</last_name>
      <phone>303-724-7942</phone>
      <email>catherine.lozapone@ucdenver.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 23, 2015</study_first_submitted>
  <study_first_submitted_qc>November 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gut microbiota composition</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

